CA2176753C - Drug delivery ptca catheter and method - Google Patents
Drug delivery ptca catheter and method Download PDFInfo
- Publication number
- CA2176753C CA2176753C CA002176753A CA2176753A CA2176753C CA 2176753 C CA2176753 C CA 2176753C CA 002176753 A CA002176753 A CA 002176753A CA 2176753 A CA2176753 A CA 2176753A CA 2176753 C CA2176753 C CA 2176753C
- Authority
- CA
- Canada
- Prior art keywords
- balloon
- drug delivery
- inflated
- catheter
- specified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/104—Balloon catheters used for angioplasty
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1052—Balloon catheters with special features or adapted for special applications for temporarily occluding a vessel for isolating a sector
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1086—Balloon catheters with special features or adapted for special applications having a special balloon surface topography, e.g. pores, protuberances, spikes or grooves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1002—Balloon catheters characterised by balloon shape
Abstract
An intravascular material delivery dilation catheter ( 10) having a pair of longitudinally spaced inflatable balloons (20, 22) with a drug delivery region (26) defined therebetween. The catheter is ideally suited for use after a PTCA procedure, wherein the proximate balloon (20) seals the blood vessel while the distal balloon (22) is uniquely contoured when inflated to define fluid communication paths (60) therepast and proximate a blood vessel (54) to be treated. The distal balloon (22), when inflated, has four lobes but could also be textured. Each lobe is separated from the next by a groove, which groove in combination with the blood vessel inner wall forms a fluid communication path therebetween. Upon inflation of both balloons (20, 22) in a blood vessel (54), a medicament such as heparin can be injected, via the drug delivery region (26) between the inflated balloons (20, 22), wherein the medicament flows past the distal balloon (22) at a selected rate. Accordingly, a medicament can be injected directly to a treatment site rather than injected as a bolus dose, thus, a smaller dosage may be employed to minimize side effects. Alternatively, perfusion can be accomplished by only partially inflating the proximate balloon (20) to constrict flow therepast, or eliminating the proximate balloon (20) entirely, where the drug delivery region is disposed upstream of the contoured distal balloon (22).
Description
W0 95115782 PCT/IB9.lI0D316 DRUG DELIVERY PTCA CATHETER AND METHOD
Backoround of the Invention This invention relates generally to an apparatus and method for delivering a drug to a patient's vascular system after performing a percutaneous transluminal coronary angioplasty (PTCA) procedure, and more particularly to an improved catheter arrangement which facilitates delivering and concentrating a drug to a treatment site in a blood vessel.
A percutaneous transluminal coronary angioplasty (PTCA) procedure typically consists of introducing a catheter with a single inflatable balloon into a patient's vascular system and positioning the balloon proximate a stenotic lesion to be treated. With the balloon juxtaposed relative to the blockage or constriction, an inflation fluid is introduced through a lumen of the catheter and made to inflate the balloon to expand the balloon against the blockage and to spread or open the obstructed blood vessel. This catheter is then removed and a second catheter is introduced into the vascular system.
Subsequently, a medicament is introduced through the second catheter and to the site to treat the stenotic lesion to inhibit platelet aggregation at the site.
This procedure is widely used in modern medicine and is far less traumatic than prior coronary bypass surgical procedures.
Certain drugs have been found to be more ' 30 effective than others in reducing restenosis. These drugs help reduce the necessity of repeating the PTCA
procedure. For instance, there are drugs which show a tendency to inhibit smooth muscle cell growth.
Because these drugs can have undesirable side effects, it is not desirable that they be injected as
Backoround of the Invention This invention relates generally to an apparatus and method for delivering a drug to a patient's vascular system after performing a percutaneous transluminal coronary angioplasty (PTCA) procedure, and more particularly to an improved catheter arrangement which facilitates delivering and concentrating a drug to a treatment site in a blood vessel.
A percutaneous transluminal coronary angioplasty (PTCA) procedure typically consists of introducing a catheter with a single inflatable balloon into a patient's vascular system and positioning the balloon proximate a stenotic lesion to be treated. With the balloon juxtaposed relative to the blockage or constriction, an inflation fluid is introduced through a lumen of the catheter and made to inflate the balloon to expand the balloon against the blockage and to spread or open the obstructed blood vessel. This catheter is then removed and a second catheter is introduced into the vascular system.
Subsequently, a medicament is introduced through the second catheter and to the site to treat the stenotic lesion to inhibit platelet aggregation at the site.
This procedure is widely used in modern medicine and is far less traumatic than prior coronary bypass surgical procedures.
Certain drugs have been found to be more ' 30 effective than others in reducing restenosis. These drugs help reduce the necessity of repeating the PTCA
procedure. For instance, there are drugs which show a tendency to inhibit smooth muscle cell growth.
Because these drugs can have undesirable side effects, it is not desirable that they be injected as
- 2 -a bolus dose into a peripheral vein and merely allowed to be carried by the blood stream to the situs of the stenotic lesion. However, and in accordance with the present invention, if that drug can be administered directly to the lesion, a significantly smaller dose may be employed and the side effects minimized.
Heparin is one such known drug for inhibiting clotting which can be delivered by injection as a bolus but which is known to have disadvantages. For instance, some patients, such as ulcer patients or patients with high blood pressure, are contraindicated for the administration of such large amounts of heparin. Other drugs, such as aspirin or persantin, are effective in inhibiting platelet aggregation at a treated site and thus to inhibit restenosis. Anti-coagulation medications and medications adapted to treat damaged arteries and to dissolve thrombus, are also preferably dispensed after the PTCA procedure.
One particular intravascular drug delivery dilation catheter ideally suited for a PTCA procedure is that disclosed in U.S. Patent 4,994,033 which is assigned to the assignee of the present invention. This particular catheter comprises concentrically arranged flexible plastic expander members with a space defined between the walls thereof for receiving a liquid medicament. A plurality of minute holes are formed through the outer expander member. When both expander members inflate, the drug is caused to be ejected out the tiny pores of the outermost expander member and against the adjacent tissue of the blood vessel.
Heparin is one such known drug for inhibiting clotting which can be delivered by injection as a bolus but which is known to have disadvantages. For instance, some patients, such as ulcer patients or patients with high blood pressure, are contraindicated for the administration of such large amounts of heparin. Other drugs, such as aspirin or persantin, are effective in inhibiting platelet aggregation at a treated site and thus to inhibit restenosis. Anti-coagulation medications and medications adapted to treat damaged arteries and to dissolve thrombus, are also preferably dispensed after the PTCA procedure.
One particular intravascular drug delivery dilation catheter ideally suited for a PTCA procedure is that disclosed in U.S. Patent 4,994,033 which is assigned to the assignee of the present invention. This particular catheter comprises concentrically arranged flexible plastic expander members with a space defined between the walls thereof for receiving a liquid medicament. A plurality of minute holes are formed through the outer expander member. When both expander members inflate, the drug is caused to be ejected out the tiny pores of the outermost expander member and against the adjacent tissue of the blood vessel.
-3-Using this device, a significantly smaller dosage may be employed to directly treat.a stenotic .lesion.
Thisreduces the side-effects of the particular medicament. During application of the medicament, the outer expander member is in direct contact with and seals against the blood vessel inner wall to restrict perfusion of blood through the interface.
Thus, the medicament is not easily distributed throughout the entire body. _ A balloon catheter for delivering therapeutic agents is disclosed in U.S. Patent 5,049,132. This balloon catheter. comprises a first balloon encompassed by a second balloon, the second balloon having a plurality of apertures-defined therethrough for locally applying a medicament, such as heparin, to a stenotic lesion or a damagedcoronary- artery.
This inflatable outer balloon is also adapted to seal _ against a blood vessel inner wall for a short time -while the medicament is applied thereto. This device -uses the medication as the balloon inflation fluid. _.
The medication is administered in a volume and at a pre-determined pressure so that the balloon is expanded at a desired rate despite the leakage of medication through-the apertures in the balloon wall.
Both of these prior art PTCA drug delivery catheters comprise two concentric balloons rather than a pair of balloons longitudinally spaced from one another along the catheter shaft. The drug delivery region in each device is defined through the outer wall of the outermost balloon, and thus, is positioned against the blood vessel wall in close conformity therewith. Both of these devj.ces are -adapted to allow medication to be slowly absorbed through a blood vessel wall proximate the balloon, -
Thisreduces the side-effects of the particular medicament. During application of the medicament, the outer expander member is in direct contact with and seals against the blood vessel inner wall to restrict perfusion of blood through the interface.
Thus, the medicament is not easily distributed throughout the entire body. _ A balloon catheter for delivering therapeutic agents is disclosed in U.S. Patent 5,049,132. This balloon catheter. comprises a first balloon encompassed by a second balloon, the second balloon having a plurality of apertures-defined therethrough for locally applying a medicament, such as heparin, to a stenotic lesion or a damagedcoronary- artery.
This inflatable outer balloon is also adapted to seal _ against a blood vessel inner wall for a short time -while the medicament is applied thereto. This device -uses the medication as the balloon inflation fluid. _.
The medication is administered in a volume and at a pre-determined pressure so that the balloon is expanded at a desired rate despite the leakage of medication through-the apertures in the balloon wall.
Both of these prior art PTCA drug delivery catheters comprise two concentric balloons rather than a pair of balloons longitudinally spaced from one another along the catheter shaft. The drug delivery region in each device is defined through the outer wall of the outermost balloon, and thus, is positioned against the blood vessel wall in close conformity therewith. Both of these devj.ces are -adapted to allow medication to be slowly absorbed through a blood vessel wall proximate the balloon, -
- 4 -and are not adapted to flush a large dose of a medicament past a treatment site to bathe the site.
It is accordingly a principle object of the present invention to provide an improved dilation catheter suitable for injecting a variety of drugs directly to a treatment site.
The invention provides an intravascular drug delivery catheter, comprising: an elongated, flexible, tubular catheter shaft having a proximal end and a distal end with a first and second lumen extending therealong, said shaft having an inflatable balloon disposed at the distal end thereof and with a drug delivery region disposed between said proximal end and said balloon, said first lumen being in fluid communication with said balloon and said second lumen being in communication with said drug delivery region, said balloon when inflated having an outer contoured surface for creating a fluid flow path from said drug delivery region and along said balloon outer surface when said balloon is inflated in a patient's blood vessel.
The invention also provides an intravascular drug delivery dilation catheter comprising: an elongated, flexible, tubular catheter shaft having a proximal end and a distal end with a first, second and third lumen each extending therealong, said shaft having first and second inflatable balloons longitudinally spaced from one another proximate said distal end and with a drug delivery region disposed between said first and second balloons, said first and second lumens being in fluid communication with said first and second balloons, respectively, and said third lumen being in fluid - 4a -communication with said drug delivery region, said second balloon when inflated having an outer contoured surface for creating a fluid flow path from said drug delivery region and along said second balloon outer surface when said second balloon is inflated in a patient's blood vessel.
The improved dilation catheters disclosed herein are suitable for injecting a drug during the course of or after a PTCA procedure. The dilation catheter permits administration of a liquid medicament or other suitable substance directly to the lesion being treated so as to inhibit restenosis. The dilation catheter is suitable for use in or after a PTCA
procedure and which restricts blood flow in the blood vessel while a medicament is effectively applied to the site of a stenotic lesion.
Another object of the present invention is to provide a catheter suitable for performing perfusion.
The contoured outer balloon surface when inflated defines a plurality of fluid W O 95!15782 PCTIIB94100316 _5_ passages between the periphery of. the second balloon -and the inner wall of the blood vessel being treated. -Thus, a medicament can be dispensed into the void between the inflated balloons and. allowed to flow slowly past the tissue.o_the-blood vessel wall adjacent the inflated second balloDn to effectively bathe the treated site with the medicament. The first balloon is inflated to totally seal the blood __e vessel proximal and upstream of the. treatment site, while the second balloon is inflated to constrict flow in the blood vessel to allow leakage of _ medication therepast and adjacent the blood vessel wall. If desired, the inflatedsecond balloon could be expanded to spread the bloodves5el as the medicament flows therepast. An aspiration port is in -communication with the drug delivery region such that the void defined between the pair of inflated balloons can be flushed and aspirated before and after dispensing the medicament. to-increase the drug eff=ectiveness, such as during ar after-the PTCA
procedure.
In the preferred embodiment, the second balloon has a plurality of lobes when inflated such that a fluid path is defined between each pair of adjacent lobes: With four lobes, four longitudinal fluid _ paths are created in cooperation with the blood vessel's inner wall, each channel extending along the groove between the defined lobes. However, other __ designs can be implemented as well wherein a portion . 30 of the second inflatable balloon engages the blood vessel wall while another portion is spaced from the _.
blood vessel wall to-define one or more channels therebetween. Of course, the contours of the second balloon can be designed such that either~large-or W 0 95115782 PCT/T89.1/00316 small, few o~ many, straight, curved or spiraled fluid paths result when the second balloon is inflated. The channels are created by selectively choosing the thickness of the second balloon walls, the walls being thinner proximate the crowns of the lobes than proximate the valleys such that the lobes tend to stretch more than the va:Ileys when the balloon in W flated. Alternatively, the second' balloon carz have walls of uniform thickness, wherein the outer surface is textured and has a rough surface, or includes a plurality of outwardly-extending spaced protrusions.
In an alternative preferred embodiment, the first ar pr~cimal balloon can also be contoured when inflated, only partially inflated, or eliminated altogether to provide perfusion. Thus, a medicament can be effectively mixed with a small flow of blood and together allowed to flow slow7.y past a selected portion of the blood vessel. Accordingly, a single balloon catheter can provide effective localized drug treatment as well. -Figure Z is a greatly enlarged,-partially sectioned two-balloon intravascular drug delivery catheter disposed- in a blood vessel -in accordance with a preferred embodiment of the present invention;
Figure 2 is a greatly enlarged, partially sectioned view of the catheter illustrating the various lumens, balloons, and drug delivery region;
Figure 3 is-a--cross-sectional view 3-3 taken in Figure 1 of -the proximal balloon illustrating the several lumens extending through the catheter;
Figure 4 is a cross-sectional view 4-4 taken in , Figure_1 of the inflated contouredd'lstal balloon in a coronary a~teiy and defining a plurality of fluid W095f15782 PC1'IIB94100316 21 ~6~5~'.
_7_ channels;
Figure-S is a cross-sectional view taken at..3-3 in Figure 1 where inflation lumens 30 and 32 are in fluid communication with each other;
Figure 6 is a.greatly enlarged, partially __ sectioned view of a single-balloon intravascular drug delivery catheter disposed in a blood vessel in -.
accordance with an alternative preferred embodiment of the invention suitable for perfusion;
Figure 7 is a cross-sectional view taken at 7-7 in Figure 6 illustrating the,-several lumens extending through the catheter;
Figure 8 is a sectional view 4-4 taken in Figure , 1 where the distalballoon has a textured outer surface; and Figure 9 is a sectional view 4-4 taken in Figure 1 where the distal balloon is comprised of a plurality of outwardly-extending protrusions. -Other objects, features and advantages .af the present invention will become apparent to those skilled in the art through the Description of the _.
Preferred Embodiment, Claims, and drawings herein wherein like numerals refer to like elements. , Referring now to Figures 1 and 2, an intravascular drug-delivery dilation catheter comprising a preferred-embodiment o the present invention is generally shown at 10. It is seen to include first, second and third_conceritrically or _-coaxially disposed elongated flexible plastic tubular members identified by numerals 12, 14 and 16, respectively. The three tubes may typically be . approximately 135 cms. in length and the outermost tube 12 dimensioned to readily pays through the portion of the vascular system proximal of the W0 95115782 PCf/IB9a/00316 21'~ 6'7 5 3 treatment site. The arrangement is depicted as an over-the-wire system in that it may be made to pass over an elongated guidewife 18 once that guidewire has been muted through a guide catheter (not shown) with the distal end of the guidewire passing'through the site-of the lesion -or treatment site and beyond.
At the distal end of outermost tube-12 is a pair of inflatable balloons shown as a proximal balloon 2D
and a distal balloon 22. As is illustrated, proximal balloon 20 is generally°-elongated arid cylindrical in shape when inflated. D-istal balloon 22 is particularly characterized-as being-non-circular- and contoured when inflated such that a plurality of equidistant radially extending lobes are. defined.
Alternatively, the distal balloon s contour can be textured and have a rough surface (Figure-8), or comprise a-plurality of outwardly extending protrusions (Figure 91. Two balloons may be fabricated from PET as non-disten5ible plastic members, or from silicone, nylon, or polyethylene as-distensible plastic members, each appropriately bonded to the catheter body 12 as shown. The lobes are created by controlling the thickness of the balloon wall when manufactured (See Figure 4).
Specifically, the walls are more elastic and thin at some portions to define the crowns of the lobes when inflated, and relatively thicker-a~ other sections and which stretch less when inflated to define valleys. Alternatively, the degree of distensibility of the balloon in -different zones can be varied by appropriately irradiating the plastic material to affect the degree of cross-linking o~ the molecules.
When inflated, a longitudinal groove 24 is defined between adjacent lobes which serves as a fluid path > ;
along distal balloon 22 when it is inflated within a blood vessel (see Figure 4). Alternatively, the balloon 22 can be textured when inflated to allow fluid flow therepast, as shown in Figure 8, or comprise a plurality of outwardly extending _ protrusions spaced from one another to define a fluid path therepast, as shown in Figure 9.
A drug delivery region 26 is formed along outermost tube 12 between proximal balloon 20 and 1D distal balloon 22, the tube 12 in this region including a plurality of pores or apertures 28 fox dispensing medication and/or aspirating fluid present between the inflated.balloons once the.catheter has been inserted in a blood vessel.- As can be seen from s he partially broken-away and sectioned portion of Figures 1 and 2, a first.lumen 30 is in fluid -communication with the interior of proximal balloon at opening 31. A second lumen 32 extends the length of tubular member 12 and is in fluid -_ 20 communication with distal balloon 22 at opening 33 and terminates thereat. A third lumen 34, also extending the full length of the tubular member 12 is in fluid communication with drug deliuery region 26 and consequently apertures 28. A further lumen 36 extends through the center of tube 16 and slidably receives guidewire I8 as shown.
First and second inflation lumens 30 and 32 are isolated from one-another, as shown in Figure 3, such that both proximal balloon 20 and distal balloon 22 . 30 can be independently inflated by introducing an inflation fluid through ports on the catheter hub 44.
it is to be recognized that balloon -However , inflation lumens 30 and 32 could be in fluid -communication with one another, as shown in Figure S, WO 95115782 - PCTI189.i/0031G
such that both balloons 20 and 2Z will be simultaneously inflated by a single fluid source. An additional lumen 40 is provided in fluid communication with lumen 34 for aspirating fluid from perfusion region 26. However; lumens 34 and 40 could be isolated from one another as well, with lumen 40 accessible from a dedicated port at the handle such that fluid can be separately injected and/or aspirated via both lumens. -Suitably attached to.the proximal end of the catheter assembly i~ a molded plastic hub 44 having a trio of ports 46, 48 and 50, individually communicating with the lumens 3D, 32 and 34. The ports 46, 48 and 50 maybe-Luer fittings for facilitating the attachment of an inflation tool such as a syringe of the type shown in the Goodin et al.
U.S. Patent-No. 4,723,938, which is assigned to the assignee-of the present invention.
Disposed on the proximal end of the hub 44 is a 2D stub 52 having a bore which joins to the lumen 36 of the innermost tube 16 for accommodating the guidewire 18. When the guidewire ie removed, the lumen 36 of the innermost tube may be utilized to perfuse blood distally of the treatment site toinhibit ischemia downstream or to introduce a contrast-media.
Alternatively, the lumen 36 can be used as a way of measuring pressure.at the treatment site.
The concentric catheter bodies 12, 14 and 16 may be made from a variety of materials now commonly used in fabricating angioplasty and angiographic catheters. Typical materials are PVC, nylon and polyurethane. The guidewire 18 may be fabricated from stainless steel also in accordance with techniques well known in the patent literature.
Referring to Figure 1, in use, the guidewire 18 would conventionally be routed through an introducer __ or guide catheter (not shown)and across the lesion or site to be treated in blood vessel 54. Following that, the distal end of the.innermost tube 16 is fitted over the proximal end of the guidewire and then advanced along the guidewire until the lobed -distal balloon 22 is juxtapose3 proximate-the s-ite to -be treated. The proximate balloon 20 will then be positioned upstream (proximal) thereof. Figure 1 shows proximal balloon 20 and distal balloon 22 in their inflated configuration within blood vessel 54, it being understood that during the routing -operation, those balloons would be deflated and tightly wrapped to conform to the exterior of tubular member 12.
Once thedistal end of catheter 10 is appropriately positioned with the aid of a radiopaque marker band 56, an inflation fluid is next injected through proximal port 46 and thus through lumen 30, to fully inflate proximal balloon 20, thus sealing the blood vessel such as a coronary artery. However, if perfusion is desired, first balloon 20 can be only partially inflated to float in the blood vessel and constrict flow, comprised of a contoured balloon when inflated like distal balloon 22, or eliminated altogether as will be discussed shortly in reference to Figure 6. Next, an inflation ~luid will be injected through port 48 and thus through lumen 3-2 and into the interior of lobed distal balloon 22 until this balloon-is at least partially inflated and disposed proximate the vessel wall to constrict flow therethrough, and may or may not-engage the blood vessel inner wall. Preferably, the distal balloon - -W
W 0 95115782 PCT/IB9~100316 '~~,~~f'~~
22 is fully inflated and engages the blood vessel wall at thesite of the lesion to engage the lesion (see Figures 4, 8 and 9). Once inflated, a plurality of fluid paths or channels 60 are defined by the valleys of ~ he--lobed configuration, one between each lobevalley 62 and the blood vessel wall 64 as shown in Figure 4.
When inflated, the crown of each lobe 62 engages and seals with the inner proximal wall of blood vessel 54. -However, the plurality of fluid paths 60 remain open to allow fluid communication across the balloon's surface, as shown in Figures 1 and 4.
Next, a selected dispersant, such as heparin or other suitable drxxg containing liquid for inhibiting formation of a thrombus, or aspirin or persantin for inhibiting ~Iatelet aggregation at the treatment site, is introduced through the distal Luer port 50 and-through lumen 34 to, the confines of drug delivery region 26 aiW thus dispensed through apertures 28 into the void defined between inflated balloons 20 and 22. Once this void is filled with medication, additional injection of medication into the void causes: the medication to be swept past inflated distal balloon 22 at a corresponding 'and controllable rate through the fluid channels 60 defined by longitudinally extending grooves 24 and the blood vessel inner caall, and in intimate contact with the treatment site, as shown in Figure 1 by the arrows illustrating flow patterns. The first inflated balloon seals the blood vessel 54 upstream from the _ treatment site such that the drug does not wash away too quickly past the drug treatment site, and further , ensures that only the medication will flow past the drug treatment site.
W095/15782 ~ PCTIIB94100316 _13_ By selecting an appropriate depth of grooves 24 between adjacent lobes 62, the rate at which this dispensed medication flows past expanded distal lobe 22-can be selected. Accordingly, the shallower the groove 24, the slower rate at which medication is pushed therepast. Similarly, the number of grooves 24 defined can'also be chosen,to control the rate at which medication flows therepast. For instance, distal balloon 22 can be designed to have only a pair -of .lobes (when inflated) and a corresponding pair of grooves 24 for accommodating fluid flow: If-desired, the longitudinally extending grooves 24.can be non-linear, curved, or spiraled rather than linear to ._ selectively alter the rate and pattern at which medicament flows therepast. Alternatively, the distal balloon 22 can be textured and have a rough surface wheninflated (see.Figure 8) or include a plurality of lobes or protrusions (see Figure 9) so ;-that the balloon 22 only partially seals blood vessel 54 when inflated, thus allowing medication to flow slowly therepast.
Accordingly, one key feature ofthe present invention is that distal balloon 22 is uniquely contoured when inflated to seal against a portion of a blood vessel 54 at one portion, but which remains spaced from the blood vessel wall at other grooved portions thereof to allow leakage and communication --of a dispensed-medicament therepast proximate a treatment site. However, the distal balloon 22 can - also be only partially inflated anddisposed -proximate the vessel inner wall but spaced therefrom, in a floating arrangement, to constrict flow of medication therepast. The contour of the inflated distal balloon 22 is defined when inflated by proper WO 95!15782 PCfIIB9.110031G
attention to wall thickness at time of manufacture, as shown in Figure 4. Alternatively, the wall can have a unifoizn thickness but which has a textured exterior surface (Figure 8), or which includes a plurality of outwardly extending spaced protrusions (Figure 9). Radiopaque marker 56 can be used to locate distal balloon 22 adjacent or slightly upstream from a site to be treated.
Prior to injection of a medicament, the apertures of drug delivery region 26 can be used in combination with lumen 3~I and/or 40 to flood ahd flush the void between the inflated balloons and to aspirate this and other fluids which may be disposed therebetween_ Thus, when a medicament is subsequently injected via the drug delivery region 26 into this void, the medicament will not be diluted and thus can-be concentrated against and bathe the blood vessel wall to be-treated: "Flushing fluids, such as saline, are commonly used. Thus, the blood vessel wall can then be doped with the medicament effectively.
After the PTCA procedure, the blood vessel wall , -such as a coronary artery, can be only occluded for a short period of time, e.g. one.minute_ During this time, anticoagulation drugs or drugs created to dissolve clots can be infected using the present apparatus and method. The combination of the pair of longitudinally spaced balloons with-a drug deliveiy region defined therebetween, wherein the distal balloon is contoured wheh 'inflated, has been found to be effectivein providing a long-Eerm patency to the treated blood vessel or the coronary artery. The , size and shapes'of fluid paths 60 can be custom designed through appropriately designed Iobes 62 and W095115782 PCTIIB9a/00316 ~'~3 .
channels 24 so that they are not easily plugged, and so that the fluid flow rate of the medicament flowing therepast can be particularly chosen. Thus, one key feature of the present invention is that the rate at S which medicament can flow past a treatment site can be chosen by using a particularly designed distal balloon 22. While purely exemplary, drugs may include aspirin-or a persantin for inhibiting -platelet aggregation at the site, heparin or prostaglandin for inhibiting clotting, or other drugs found to be effective in inhibiting smooth muscle cell growth.
While an inflatable proximal balloon 20 is ideal for sealing a blood vessel before dispensing a medicament via drug delivery region 26, it needs to be recognized that limitation to an inflatable balloon is not to be inferred for other devices and -methods for sealing or constricting a blood vessel upstream from drug delivery region 26 can be used as well. Thus, the particular method of the present invention encompasses first sealing a blood vessel . -upstream from a chosen blood vessel site, such as the locus of a stenotic lesion, in the course of or aftQr a PTCA, inflating a custom designed balloon or flow impeding member at or downstream from this site, and then injecting a medicamentbetween the proximal balloon (sealing means) and the distal contoured balloon, such that the medicament flows past the contoured distal balloon and adjacent the site to be . 30 treated.
While four lobes, such as a clover design, is the contour of the preferred embodiment, it is also to be recognized that different contours such as outwardly-extending protrusions or textures, W0 93115782 PCTlIB9.1100316 ~.~.~ ~~ ~3 equivalent i~n function to rounded lobes, as shown, are suitable for the present invention as.well. The resulting recesses, in combination with the blood vessel inner wall when the contoured balloon is inflated, dorm a fluid path such that medicament can leak therepast at a controlled rate.Accordingly, limitations to the. particular design-o~ the fluid path is not to be .inferred. Further yet, the amount of inflation fluidinjected into distal balloon 22 can be selectively pontrolled as well, via port 48, such that this balloon can be selectively and controllably inflated to selectively control the cross section opening of paths.60 as well. Thus, the rate at vrhich medicament flows past.distal balloon 22 proximate the treatment sitecan be. selectively controlled.using a single apparatus, such as the distal balloon 22 shown in Figure 1.
In an aiternative.preferred embodiment o~ the .
present invention as shown at 70 in Figure 6, perfusion can be performed by the present invention as well. By only partially inflating proximal balloon 20, providing an inflated proximal balloon which is contoured, such as one identical to. balloon 22 in FiguY~ 1 or which is textured ..(Figure 8), or providing a proximal balloon-20 including-:outwdrdly-extending protrusions (Figure ~), or-eliminating proximal balloon 2D altogether as shown in Figure 6, perfusion is possible and will now be discussed.
The single-balloon catheter 70 in Figure 6 is very similar to the two-balloon catheter shown in Figure L with -the exception that only a single contoured distal balloon 22 is provided with drug delivery region 26.be~"~,g defined proximal and upstream therefrom. Correspondingly, a reduced WO 95!15782 PCTlIB94100316 ,.' ;
_1~_ number of lumens and ports are required for operation of this catheter. Specifically, a first lumen 30 is provided which communicates medicament from port 46 to drug delivery region-26 and pores 28, and a second lumen 32 which extends from port 48 to and terminates -at distal-balloon 22 fbr inflation thereof as previously described with regards to the catheter 1D
of Figure 1. Lumen 36 is provided for receiving guidewire 18 as shown in Figure 7.
To allow perfusion, restricted and reduced blood -flow is permitted through fluid passageways 60 while -medicament is a.njected upstream of inflated distal -balloon 22 via drug delivery region 26 and thus mixes therewith. Both the blood and medicament will together be slowly swept past inflated contoured distal balloon 22 and in close proximity with the blood vessel inner wall to bathe the site, such as -during or after a PTCA procedure. For instance, distal balloon 22 can be inflated to expand the blood vessel to reduce stenosis as medicament is being swept therepast, or implemented after a PTCA-procedure is performed by a previously introduced catheter. Any of the embodiments shown for distal balloon 22, such as the lobed balloon (Figure 1), a textured balloon (Figure 8), or a balloon including protrusions (Figure 9) are suitable and can be implemented as desired by the physician.
In summary, limitation to the particular contours of contoured distal balloon 22, or -- 30 limitation to implementing proximal balloon 20 in a partially or totally inflated configuration, is not to be inferred. Rather, providing a distal contoured balloon 22 when inflated with a drug delivery region disposed proximate and upstream thereof is one of the W0 95115782 PCTIIB9.1100316 21,~ 6~~3 primary features of the present invention. The , proximal balloon 2D- can be eliminated altogether or , left uninflated if-desired. Further, the present invention can be implemented during or after a PTCA
procedure, and may incorporate perfusion if desired.
This invention has been described herein in considerable detail in,order to.comply with the Patent Statutes and to provide those skilled in the art with the information needed to apply the novel principlesand to construct and usesuch pecialized components as arerequired.- However, it is to be understood that the invention can be_c~rried out by specifically different. equipment and devices, and that various modifications, both as to the equipment details and operating procedures, can be accomplished without departing from the scope of the invention itself.
It is accordingly a principle object of the present invention to provide an improved dilation catheter suitable for injecting a variety of drugs directly to a treatment site.
The invention provides an intravascular drug delivery catheter, comprising: an elongated, flexible, tubular catheter shaft having a proximal end and a distal end with a first and second lumen extending therealong, said shaft having an inflatable balloon disposed at the distal end thereof and with a drug delivery region disposed between said proximal end and said balloon, said first lumen being in fluid communication with said balloon and said second lumen being in communication with said drug delivery region, said balloon when inflated having an outer contoured surface for creating a fluid flow path from said drug delivery region and along said balloon outer surface when said balloon is inflated in a patient's blood vessel.
The invention also provides an intravascular drug delivery dilation catheter comprising: an elongated, flexible, tubular catheter shaft having a proximal end and a distal end with a first, second and third lumen each extending therealong, said shaft having first and second inflatable balloons longitudinally spaced from one another proximate said distal end and with a drug delivery region disposed between said first and second balloons, said first and second lumens being in fluid communication with said first and second balloons, respectively, and said third lumen being in fluid - 4a -communication with said drug delivery region, said second balloon when inflated having an outer contoured surface for creating a fluid flow path from said drug delivery region and along said second balloon outer surface when said second balloon is inflated in a patient's blood vessel.
The improved dilation catheters disclosed herein are suitable for injecting a drug during the course of or after a PTCA procedure. The dilation catheter permits administration of a liquid medicament or other suitable substance directly to the lesion being treated so as to inhibit restenosis. The dilation catheter is suitable for use in or after a PTCA
procedure and which restricts blood flow in the blood vessel while a medicament is effectively applied to the site of a stenotic lesion.
Another object of the present invention is to provide a catheter suitable for performing perfusion.
The contoured outer balloon surface when inflated defines a plurality of fluid W O 95!15782 PCTIIB94100316 _5_ passages between the periphery of. the second balloon -and the inner wall of the blood vessel being treated. -Thus, a medicament can be dispensed into the void between the inflated balloons and. allowed to flow slowly past the tissue.o_the-blood vessel wall adjacent the inflated second balloDn to effectively bathe the treated site with the medicament. The first balloon is inflated to totally seal the blood __e vessel proximal and upstream of the. treatment site, while the second balloon is inflated to constrict flow in the blood vessel to allow leakage of _ medication therepast and adjacent the blood vessel wall. If desired, the inflatedsecond balloon could be expanded to spread the bloodves5el as the medicament flows therepast. An aspiration port is in -communication with the drug delivery region such that the void defined between the pair of inflated balloons can be flushed and aspirated before and after dispensing the medicament. to-increase the drug eff=ectiveness, such as during ar after-the PTCA
procedure.
In the preferred embodiment, the second balloon has a plurality of lobes when inflated such that a fluid path is defined between each pair of adjacent lobes: With four lobes, four longitudinal fluid _ paths are created in cooperation with the blood vessel's inner wall, each channel extending along the groove between the defined lobes. However, other __ designs can be implemented as well wherein a portion . 30 of the second inflatable balloon engages the blood vessel wall while another portion is spaced from the _.
blood vessel wall to-define one or more channels therebetween. Of course, the contours of the second balloon can be designed such that either~large-or W 0 95115782 PCT/T89.1/00316 small, few o~ many, straight, curved or spiraled fluid paths result when the second balloon is inflated. The channels are created by selectively choosing the thickness of the second balloon walls, the walls being thinner proximate the crowns of the lobes than proximate the valleys such that the lobes tend to stretch more than the va:Ileys when the balloon in W flated. Alternatively, the second' balloon carz have walls of uniform thickness, wherein the outer surface is textured and has a rough surface, or includes a plurality of outwardly-extending spaced protrusions.
In an alternative preferred embodiment, the first ar pr~cimal balloon can also be contoured when inflated, only partially inflated, or eliminated altogether to provide perfusion. Thus, a medicament can be effectively mixed with a small flow of blood and together allowed to flow slow7.y past a selected portion of the blood vessel. Accordingly, a single balloon catheter can provide effective localized drug treatment as well. -Figure Z is a greatly enlarged,-partially sectioned two-balloon intravascular drug delivery catheter disposed- in a blood vessel -in accordance with a preferred embodiment of the present invention;
Figure 2 is a greatly enlarged, partially sectioned view of the catheter illustrating the various lumens, balloons, and drug delivery region;
Figure 3 is-a--cross-sectional view 3-3 taken in Figure 1 of -the proximal balloon illustrating the several lumens extending through the catheter;
Figure 4 is a cross-sectional view 4-4 taken in , Figure_1 of the inflated contouredd'lstal balloon in a coronary a~teiy and defining a plurality of fluid W095f15782 PC1'IIB94100316 21 ~6~5~'.
_7_ channels;
Figure-S is a cross-sectional view taken at..3-3 in Figure 1 where inflation lumens 30 and 32 are in fluid communication with each other;
Figure 6 is a.greatly enlarged, partially __ sectioned view of a single-balloon intravascular drug delivery catheter disposed in a blood vessel in -.
accordance with an alternative preferred embodiment of the invention suitable for perfusion;
Figure 7 is a cross-sectional view taken at 7-7 in Figure 6 illustrating the,-several lumens extending through the catheter;
Figure 8 is a sectional view 4-4 taken in Figure , 1 where the distalballoon has a textured outer surface; and Figure 9 is a sectional view 4-4 taken in Figure 1 where the distal balloon is comprised of a plurality of outwardly-extending protrusions. -Other objects, features and advantages .af the present invention will become apparent to those skilled in the art through the Description of the _.
Preferred Embodiment, Claims, and drawings herein wherein like numerals refer to like elements. , Referring now to Figures 1 and 2, an intravascular drug-delivery dilation catheter comprising a preferred-embodiment o the present invention is generally shown at 10. It is seen to include first, second and third_conceritrically or _-coaxially disposed elongated flexible plastic tubular members identified by numerals 12, 14 and 16, respectively. The three tubes may typically be . approximately 135 cms. in length and the outermost tube 12 dimensioned to readily pays through the portion of the vascular system proximal of the W0 95115782 PCf/IB9a/00316 21'~ 6'7 5 3 treatment site. The arrangement is depicted as an over-the-wire system in that it may be made to pass over an elongated guidewife 18 once that guidewire has been muted through a guide catheter (not shown) with the distal end of the guidewire passing'through the site-of the lesion -or treatment site and beyond.
At the distal end of outermost tube-12 is a pair of inflatable balloons shown as a proximal balloon 2D
and a distal balloon 22. As is illustrated, proximal balloon 20 is generally°-elongated arid cylindrical in shape when inflated. D-istal balloon 22 is particularly characterized-as being-non-circular- and contoured when inflated such that a plurality of equidistant radially extending lobes are. defined.
Alternatively, the distal balloon s contour can be textured and have a rough surface (Figure-8), or comprise a-plurality of outwardly extending protrusions (Figure 91. Two balloons may be fabricated from PET as non-disten5ible plastic members, or from silicone, nylon, or polyethylene as-distensible plastic members, each appropriately bonded to the catheter body 12 as shown. The lobes are created by controlling the thickness of the balloon wall when manufactured (See Figure 4).
Specifically, the walls are more elastic and thin at some portions to define the crowns of the lobes when inflated, and relatively thicker-a~ other sections and which stretch less when inflated to define valleys. Alternatively, the degree of distensibility of the balloon in -different zones can be varied by appropriately irradiating the plastic material to affect the degree of cross-linking o~ the molecules.
When inflated, a longitudinal groove 24 is defined between adjacent lobes which serves as a fluid path > ;
along distal balloon 22 when it is inflated within a blood vessel (see Figure 4). Alternatively, the balloon 22 can be textured when inflated to allow fluid flow therepast, as shown in Figure 8, or comprise a plurality of outwardly extending _ protrusions spaced from one another to define a fluid path therepast, as shown in Figure 9.
A drug delivery region 26 is formed along outermost tube 12 between proximal balloon 20 and 1D distal balloon 22, the tube 12 in this region including a plurality of pores or apertures 28 fox dispensing medication and/or aspirating fluid present between the inflated.balloons once the.catheter has been inserted in a blood vessel.- As can be seen from s he partially broken-away and sectioned portion of Figures 1 and 2, a first.lumen 30 is in fluid -communication with the interior of proximal balloon at opening 31. A second lumen 32 extends the length of tubular member 12 and is in fluid -_ 20 communication with distal balloon 22 at opening 33 and terminates thereat. A third lumen 34, also extending the full length of the tubular member 12 is in fluid communication with drug deliuery region 26 and consequently apertures 28. A further lumen 36 extends through the center of tube 16 and slidably receives guidewire I8 as shown.
First and second inflation lumens 30 and 32 are isolated from one-another, as shown in Figure 3, such that both proximal balloon 20 and distal balloon 22 . 30 can be independently inflated by introducing an inflation fluid through ports on the catheter hub 44.
it is to be recognized that balloon -However , inflation lumens 30 and 32 could be in fluid -communication with one another, as shown in Figure S, WO 95115782 - PCTI189.i/0031G
such that both balloons 20 and 2Z will be simultaneously inflated by a single fluid source. An additional lumen 40 is provided in fluid communication with lumen 34 for aspirating fluid from perfusion region 26. However; lumens 34 and 40 could be isolated from one another as well, with lumen 40 accessible from a dedicated port at the handle such that fluid can be separately injected and/or aspirated via both lumens. -Suitably attached to.the proximal end of the catheter assembly i~ a molded plastic hub 44 having a trio of ports 46, 48 and 50, individually communicating with the lumens 3D, 32 and 34. The ports 46, 48 and 50 maybe-Luer fittings for facilitating the attachment of an inflation tool such as a syringe of the type shown in the Goodin et al.
U.S. Patent-No. 4,723,938, which is assigned to the assignee-of the present invention.
Disposed on the proximal end of the hub 44 is a 2D stub 52 having a bore which joins to the lumen 36 of the innermost tube 16 for accommodating the guidewire 18. When the guidewire ie removed, the lumen 36 of the innermost tube may be utilized to perfuse blood distally of the treatment site toinhibit ischemia downstream or to introduce a contrast-media.
Alternatively, the lumen 36 can be used as a way of measuring pressure.at the treatment site.
The concentric catheter bodies 12, 14 and 16 may be made from a variety of materials now commonly used in fabricating angioplasty and angiographic catheters. Typical materials are PVC, nylon and polyurethane. The guidewire 18 may be fabricated from stainless steel also in accordance with techniques well known in the patent literature.
Referring to Figure 1, in use, the guidewire 18 would conventionally be routed through an introducer __ or guide catheter (not shown)and across the lesion or site to be treated in blood vessel 54. Following that, the distal end of the.innermost tube 16 is fitted over the proximal end of the guidewire and then advanced along the guidewire until the lobed -distal balloon 22 is juxtapose3 proximate-the s-ite to -be treated. The proximate balloon 20 will then be positioned upstream (proximal) thereof. Figure 1 shows proximal balloon 20 and distal balloon 22 in their inflated configuration within blood vessel 54, it being understood that during the routing -operation, those balloons would be deflated and tightly wrapped to conform to the exterior of tubular member 12.
Once thedistal end of catheter 10 is appropriately positioned with the aid of a radiopaque marker band 56, an inflation fluid is next injected through proximal port 46 and thus through lumen 30, to fully inflate proximal balloon 20, thus sealing the blood vessel such as a coronary artery. However, if perfusion is desired, first balloon 20 can be only partially inflated to float in the blood vessel and constrict flow, comprised of a contoured balloon when inflated like distal balloon 22, or eliminated altogether as will be discussed shortly in reference to Figure 6. Next, an inflation ~luid will be injected through port 48 and thus through lumen 3-2 and into the interior of lobed distal balloon 22 until this balloon-is at least partially inflated and disposed proximate the vessel wall to constrict flow therethrough, and may or may not-engage the blood vessel inner wall. Preferably, the distal balloon - -W
W 0 95115782 PCT/IB9~100316 '~~,~~f'~~
22 is fully inflated and engages the blood vessel wall at thesite of the lesion to engage the lesion (see Figures 4, 8 and 9). Once inflated, a plurality of fluid paths or channels 60 are defined by the valleys of ~ he--lobed configuration, one between each lobevalley 62 and the blood vessel wall 64 as shown in Figure 4.
When inflated, the crown of each lobe 62 engages and seals with the inner proximal wall of blood vessel 54. -However, the plurality of fluid paths 60 remain open to allow fluid communication across the balloon's surface, as shown in Figures 1 and 4.
Next, a selected dispersant, such as heparin or other suitable drxxg containing liquid for inhibiting formation of a thrombus, or aspirin or persantin for inhibiting ~Iatelet aggregation at the treatment site, is introduced through the distal Luer port 50 and-through lumen 34 to, the confines of drug delivery region 26 aiW thus dispensed through apertures 28 into the void defined between inflated balloons 20 and 22. Once this void is filled with medication, additional injection of medication into the void causes: the medication to be swept past inflated distal balloon 22 at a corresponding 'and controllable rate through the fluid channels 60 defined by longitudinally extending grooves 24 and the blood vessel inner caall, and in intimate contact with the treatment site, as shown in Figure 1 by the arrows illustrating flow patterns. The first inflated balloon seals the blood vessel 54 upstream from the _ treatment site such that the drug does not wash away too quickly past the drug treatment site, and further , ensures that only the medication will flow past the drug treatment site.
W095/15782 ~ PCTIIB94100316 _13_ By selecting an appropriate depth of grooves 24 between adjacent lobes 62, the rate at which this dispensed medication flows past expanded distal lobe 22-can be selected. Accordingly, the shallower the groove 24, the slower rate at which medication is pushed therepast. Similarly, the number of grooves 24 defined can'also be chosen,to control the rate at which medication flows therepast. For instance, distal balloon 22 can be designed to have only a pair -of .lobes (when inflated) and a corresponding pair of grooves 24 for accommodating fluid flow: If-desired, the longitudinally extending grooves 24.can be non-linear, curved, or spiraled rather than linear to ._ selectively alter the rate and pattern at which medicament flows therepast. Alternatively, the distal balloon 22 can be textured and have a rough surface wheninflated (see.Figure 8) or include a plurality of lobes or protrusions (see Figure 9) so ;-that the balloon 22 only partially seals blood vessel 54 when inflated, thus allowing medication to flow slowly therepast.
Accordingly, one key feature ofthe present invention is that distal balloon 22 is uniquely contoured when inflated to seal against a portion of a blood vessel 54 at one portion, but which remains spaced from the blood vessel wall at other grooved portions thereof to allow leakage and communication --of a dispensed-medicament therepast proximate a treatment site. However, the distal balloon 22 can - also be only partially inflated anddisposed -proximate the vessel inner wall but spaced therefrom, in a floating arrangement, to constrict flow of medication therepast. The contour of the inflated distal balloon 22 is defined when inflated by proper WO 95!15782 PCfIIB9.110031G
attention to wall thickness at time of manufacture, as shown in Figure 4. Alternatively, the wall can have a unifoizn thickness but which has a textured exterior surface (Figure 8), or which includes a plurality of outwardly extending spaced protrusions (Figure 9). Radiopaque marker 56 can be used to locate distal balloon 22 adjacent or slightly upstream from a site to be treated.
Prior to injection of a medicament, the apertures of drug delivery region 26 can be used in combination with lumen 3~I and/or 40 to flood ahd flush the void between the inflated balloons and to aspirate this and other fluids which may be disposed therebetween_ Thus, when a medicament is subsequently injected via the drug delivery region 26 into this void, the medicament will not be diluted and thus can-be concentrated against and bathe the blood vessel wall to be-treated: "Flushing fluids, such as saline, are commonly used. Thus, the blood vessel wall can then be doped with the medicament effectively.
After the PTCA procedure, the blood vessel wall , -such as a coronary artery, can be only occluded for a short period of time, e.g. one.minute_ During this time, anticoagulation drugs or drugs created to dissolve clots can be infected using the present apparatus and method. The combination of the pair of longitudinally spaced balloons with-a drug deliveiy region defined therebetween, wherein the distal balloon is contoured wheh 'inflated, has been found to be effectivein providing a long-Eerm patency to the treated blood vessel or the coronary artery. The , size and shapes'of fluid paths 60 can be custom designed through appropriately designed Iobes 62 and W095115782 PCTIIB9a/00316 ~'~3 .
channels 24 so that they are not easily plugged, and so that the fluid flow rate of the medicament flowing therepast can be particularly chosen. Thus, one key feature of the present invention is that the rate at S which medicament can flow past a treatment site can be chosen by using a particularly designed distal balloon 22. While purely exemplary, drugs may include aspirin-or a persantin for inhibiting -platelet aggregation at the site, heparin or prostaglandin for inhibiting clotting, or other drugs found to be effective in inhibiting smooth muscle cell growth.
While an inflatable proximal balloon 20 is ideal for sealing a blood vessel before dispensing a medicament via drug delivery region 26, it needs to be recognized that limitation to an inflatable balloon is not to be inferred for other devices and -methods for sealing or constricting a blood vessel upstream from drug delivery region 26 can be used as well. Thus, the particular method of the present invention encompasses first sealing a blood vessel . -upstream from a chosen blood vessel site, such as the locus of a stenotic lesion, in the course of or aftQr a PTCA, inflating a custom designed balloon or flow impeding member at or downstream from this site, and then injecting a medicamentbetween the proximal balloon (sealing means) and the distal contoured balloon, such that the medicament flows past the contoured distal balloon and adjacent the site to be . 30 treated.
While four lobes, such as a clover design, is the contour of the preferred embodiment, it is also to be recognized that different contours such as outwardly-extending protrusions or textures, W0 93115782 PCTlIB9.1100316 ~.~.~ ~~ ~3 equivalent i~n function to rounded lobes, as shown, are suitable for the present invention as.well. The resulting recesses, in combination with the blood vessel inner wall when the contoured balloon is inflated, dorm a fluid path such that medicament can leak therepast at a controlled rate.Accordingly, limitations to the. particular design-o~ the fluid path is not to be .inferred. Further yet, the amount of inflation fluidinjected into distal balloon 22 can be selectively pontrolled as well, via port 48, such that this balloon can be selectively and controllably inflated to selectively control the cross section opening of paths.60 as well. Thus, the rate at vrhich medicament flows past.distal balloon 22 proximate the treatment sitecan be. selectively controlled.using a single apparatus, such as the distal balloon 22 shown in Figure 1.
In an aiternative.preferred embodiment o~ the .
present invention as shown at 70 in Figure 6, perfusion can be performed by the present invention as well. By only partially inflating proximal balloon 20, providing an inflated proximal balloon which is contoured, such as one identical to. balloon 22 in FiguY~ 1 or which is textured ..(Figure 8), or providing a proximal balloon-20 including-:outwdrdly-extending protrusions (Figure ~), or-eliminating proximal balloon 2D altogether as shown in Figure 6, perfusion is possible and will now be discussed.
The single-balloon catheter 70 in Figure 6 is very similar to the two-balloon catheter shown in Figure L with -the exception that only a single contoured distal balloon 22 is provided with drug delivery region 26.be~"~,g defined proximal and upstream therefrom. Correspondingly, a reduced WO 95!15782 PCTlIB94100316 ,.' ;
_1~_ number of lumens and ports are required for operation of this catheter. Specifically, a first lumen 30 is provided which communicates medicament from port 46 to drug delivery region-26 and pores 28, and a second lumen 32 which extends from port 48 to and terminates -at distal-balloon 22 fbr inflation thereof as previously described with regards to the catheter 1D
of Figure 1. Lumen 36 is provided for receiving guidewire 18 as shown in Figure 7.
To allow perfusion, restricted and reduced blood -flow is permitted through fluid passageways 60 while -medicament is a.njected upstream of inflated distal -balloon 22 via drug delivery region 26 and thus mixes therewith. Both the blood and medicament will together be slowly swept past inflated contoured distal balloon 22 and in close proximity with the blood vessel inner wall to bathe the site, such as -during or after a PTCA procedure. For instance, distal balloon 22 can be inflated to expand the blood vessel to reduce stenosis as medicament is being swept therepast, or implemented after a PTCA-procedure is performed by a previously introduced catheter. Any of the embodiments shown for distal balloon 22, such as the lobed balloon (Figure 1), a textured balloon (Figure 8), or a balloon including protrusions (Figure 9) are suitable and can be implemented as desired by the physician.
In summary, limitation to the particular contours of contoured distal balloon 22, or -- 30 limitation to implementing proximal balloon 20 in a partially or totally inflated configuration, is not to be inferred. Rather, providing a distal contoured balloon 22 when inflated with a drug delivery region disposed proximate and upstream thereof is one of the W0 95115782 PCTIIB9.1100316 21,~ 6~~3 primary features of the present invention. The , proximal balloon 2D- can be eliminated altogether or , left uninflated if-desired. Further, the present invention can be implemented during or after a PTCA
procedure, and may incorporate perfusion if desired.
This invention has been described herein in considerable detail in,order to.comply with the Patent Statutes and to provide those skilled in the art with the information needed to apply the novel principlesand to construct and usesuch pecialized components as arerequired.- However, it is to be understood that the invention can be_c~rried out by specifically different. equipment and devices, and that various modifications, both as to the equipment details and operating procedures, can be accomplished without departing from the scope of the invention itself.
Claims (20)
1. An intravascular drug delivery dilatation catheter (10) comprising:
an elongated, flexible, tubular catheter shaft (12) having a proximal end and a distal end with a first, second and third lumen (30,32,34) each extending therealong, said shaft having first and second inflatable balloons (20,22) longitudinally spaced from one another proximate said distal end and with a drug delivery region (26) disposed between said first and second balloons (20,22) said first and second lumens (30,32) being in fluid communication with said first and second balloons (20,22) respectively, and said third lumen (34) being in fluid communication with said drug delivery region (26), said second balloon (22) when inflated having an outer contoured surface for creating a fluid flow path from said drug delivery region (26) and along said second balloon (22) outer surface when said second balloon (22) is inflated in a patient's blood vessel (54).
an elongated, flexible, tubular catheter shaft (12) having a proximal end and a distal end with a first, second and third lumen (30,32,34) each extending therealong, said shaft having first and second inflatable balloons (20,22) longitudinally spaced from one another proximate said distal end and with a drug delivery region (26) disposed between said first and second balloons (20,22) said first and second lumens (30,32) being in fluid communication with said first and second balloons (20,22) respectively, and said third lumen (34) being in fluid communication with said drug delivery region (26), said second balloon (22) when inflated having an outer contoured surface for creating a fluid flow path from said drug delivery region (26) and along said second balloon (22) outer surface when said second balloon (22) is inflated in a patient's blood vessel (54).
2. The drug delivery dilation catheter (10) as specified in Claim 1 wherein said second balloon (22) comprises a plurality of lobes when inflated, there being a longitudinal fluid path between each pair of adjacent ones of said lobes.
3. The drug delivery dilation catheter (10) as specified in Claim 2 wherein said second balloon (22) has a balloon wall of a varying thickness to define said lobes when inflated.
4. The drug delivery dilation catheter (10) as specified in Claim 2 wherein said fluid paths are located angularly equidistantly from one another to facilitate uniform passage of a medication dispensed from said drug delivery region (26) along said outer surface of said second balloon (22).
5. The drug delivery catheter (10) as specified in Claim 1 wherein said second balloon (22) outer surface is textured when inflated for creating said fluid flow path.
6. The drug delivery catheter (10) as specified in Claim 1 wherein said second balloon (22) outer surface includes a plurality of outwardly extending protrusions when inflated.
7. The drug delivery catheter (10) as specified in Claim 1 wherein said second balloon (22) is comprised of a distensible material.
8. The drug delivery catheter (10) as specified in Claim 1 wherein said second balloon (22) is comprised of a nondistensible material.
9. The drug delivery dilation catheter (10) as specified in Claim 1 wherein said first and second lumen (30,32) are in fluid communication with each other to facilitate simultaneous inflation of said first and second balloons (20,22).
10. The drug delivery dilation catheter (10) as specified in Claim 1 further including a fourth lumen extending therethrough from said proximal end to said distal end for receiving a guidewire (18) therethrough.
11. An intravascular drug delivery catheter (70), comprising:
an elongated, flexible, tubular catheter shaft (12) having a proximal end and a distal end with a first and second lumen (30,32) extending therealong, said shaft having an inflatable balloon (22) disposed at the distal end thereof and with a drug delivery region (26) disposed between said proximal end and said balloon (22), said first lumen (30) being in fluid communication with said balloon (22) and said second lumen (32) being in communication with said drug delivery region (26), said balloon (22) when inflated having an outer contoured surface for creating a fluid flow path from said drug delivery region (26) and along said balloon outer surface when said balloon (22) is inflated in a patient's blood vessel (54).
an elongated, flexible, tubular catheter shaft (12) having a proximal end and a distal end with a first and second lumen (30,32) extending therealong, said shaft having an inflatable balloon (22) disposed at the distal end thereof and with a drug delivery region (26) disposed between said proximal end and said balloon (22), said first lumen (30) being in fluid communication with said balloon (22) and said second lumen (32) being in communication with said drug delivery region (26), said balloon (22) when inflated having an outer contoured surface for creating a fluid flow path from said drug delivery region (26) and along said balloon outer surface when said balloon (22) is inflated in a patient's blood vessel (54).
12. The drug delivery dilation catheter (70) as specified in Claim 11 wherein said balloon (22) comprises a plurality of lobes when inflated, there being a longitudinal fluid path between each pair of adjacent ones of said lobes.
13. The drug delivery dilation catheter (70) as specified in Claim 12 wherein said balloon (22) has a balloon wall of a varying thickness to define said lobes when inflated.
14. The drug delivery dilation catheter (70) as specified in Claim 12 wherein said fluid paths are located angularly equidistantly from one another to facilitate uniform passage of a medication dispensed from said drug delivery region (26) along said outer surface of said balloon (22).
15. The drug delivery catheter (70) as specified in Claim 11 wherein said balloon (22) outer surface is textured when inflated for creating said fluid flow path.
16. The drug delivery catheter (70) as specified in Claim 11 wherein said balloon (22) outer surface includes a plurality of outwardly extending protrusions when inflated.
17. The drug delivery catheter (70) as specified in Claim 11 wherein said balloon (22) is comprised of a distensible material.
18. The drug delivery catheter (70) as specified in Claim 11 wherein said balloon (22) is comprised of a nondistensible material.
19. The drug delivery dilation catheter (70) as specified in Claim 11 further including a third lumen extending therethrough from said proximal end to said distal end for receiving a guidewire (18) therethrough.
20. The drug delivery dilation catheter (70) as specified in Claim 11 wherein said drug delivery region (26) is disposed proximate said balloon (22).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/163,852 | 1993-12-07 | ||
US08/163,852 US5397307A (en) | 1993-12-07 | 1993-12-07 | Drug delivery PTCA catheter and method for drug delivery |
PCT/IB1994/000316 WO1995015782A1 (en) | 1993-12-07 | 1994-10-14 | Drug delevery ptca catheter and method |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2176753A1 CA2176753A1 (en) | 1995-06-15 |
CA2176753C true CA2176753C (en) | 2000-10-03 |
Family
ID=22591855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002176753A Expired - Fee Related CA2176753C (en) | 1993-12-07 | 1994-10-14 | Drug delivery ptca catheter and method |
Country Status (8)
Country | Link |
---|---|
US (1) | US5397307A (en) |
EP (1) | EP0732958B1 (en) |
JP (1) | JP2874800B2 (en) |
AT (1) | ATE176761T1 (en) |
AU (1) | AU682896B2 (en) |
CA (1) | CA2176753C (en) |
DE (1) | DE69416603T2 (en) |
WO (1) | WO1995015782A1 (en) |
Families Citing this family (215)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5634946A (en) | 1988-08-24 | 1997-06-03 | Focal, Inc. | Polymeric endoluminal paving process |
DE68922497T2 (en) * | 1988-08-24 | 1995-09-14 | Marvin J Slepian | ENDOLUMINAL SEAL WITH BISDEGRADABLE POLYMERS. |
ES2077519B1 (en) * | 1993-11-22 | 1996-07-01 | Fernandez De Lomana Euge Anaya | INTRAAORTIC CATHETER FOR RENAL PERFUSION AND CONSERVATION. |
US6248110B1 (en) * | 1994-01-26 | 2001-06-19 | Kyphon, Inc. | Systems and methods for treating fractured or diseased bone using expandable bodies |
US5843116A (en) * | 1996-05-02 | 1998-12-01 | Cardiovascular Dynamics, Inc. | Focalized intraluminal balloons |
US5556389A (en) * | 1994-03-31 | 1996-09-17 | Liprie; Samuel F. | Method and apparatus for treating stenosis or other constriction in a bodily conduit |
US5840064A (en) * | 1994-03-31 | 1998-11-24 | United States Surgical Corporation | Method and apparatus for treating stenosis or other constriction in a bodily conduit |
US5681278A (en) * | 1994-06-23 | 1997-10-28 | Cormedics Corp. | Coronary vasculature treatment method |
US5665063A (en) * | 1994-06-24 | 1997-09-09 | Focal, Inc. | Methods for application of intraluminal photopolymerized gels |
US5807398A (en) * | 1995-04-28 | 1998-09-15 | Shaknovich; Alexander | Shuttle stent delivery catheter |
US6045734A (en) * | 1995-05-24 | 2000-04-04 | Becton Dickinson And Company | Process of making a catheter |
US5779673A (en) * | 1995-06-26 | 1998-07-14 | Focal, Inc. | Devices and methods for application of intraluminal photopolymerized gels |
JP3306857B2 (en) * | 1995-08-04 | 2002-07-24 | ニプロ株式会社 | Vasodilator catheter |
US6283951B1 (en) | 1996-10-11 | 2001-09-04 | Transvascular, Inc. | Systems and methods for delivering drugs to selected locations within the body |
US5925054A (en) * | 1996-02-20 | 1999-07-20 | Cardiothoracic Systems, Inc. | Perfusion device for maintaining blood flow in a vessel while isolating an anastomosis |
US5769870A (en) * | 1996-02-20 | 1998-06-23 | Cardiothoracic Systems, Inc. | Perfusion device for maintaining blood flow in a vessel while isolating an anastomosis |
US5823996A (en) * | 1996-02-29 | 1998-10-20 | Cordis Corporation | Infusion balloon catheter |
WO1997038631A1 (en) * | 1996-04-18 | 1997-10-23 | Applied Medical Resources Corporation | Remote clot management |
US5833658A (en) * | 1996-04-29 | 1998-11-10 | Levy; Robert J. | Catheters for the delivery of solutions and suspensions |
US6022336A (en) | 1996-05-20 | 2000-02-08 | Percusurge, Inc. | Catheter system for emboli containment |
US6270477B1 (en) * | 1996-05-20 | 2001-08-07 | Percusurge, Inc. | Catheter for emboli containment |
US6652480B1 (en) * | 1997-03-06 | 2003-11-25 | Medtronic Ave., Inc. | Methods for reducing distal embolization |
US6958059B2 (en) | 1996-05-20 | 2005-10-25 | Medtronic Ave, Inc. | Methods and apparatuses for drug delivery to an intravascular occlusion |
US20010049517A1 (en) | 1997-03-06 | 2001-12-06 | Gholam-Reza Zadno-Azizi | Method for containing and removing occlusions in the carotid arteries |
US6186146B1 (en) | 1996-08-30 | 2001-02-13 | Delcath Systems Inc | Cancer treatment method |
US5947924A (en) | 1996-09-13 | 1999-09-07 | Angiorad, L.L.C. | Dilatation/centering catheter used for the treatment of stenosis or other constriction in a bodily passageway and method thereof |
WO1998038929A1 (en) | 1997-03-06 | 1998-09-11 | Percusurge, Inc. | Intravascular aspiration system |
US6770058B1 (en) | 1997-03-11 | 2004-08-03 | Interventional Therapies, Llc | Treatment catheter insert |
US6261260B1 (en) * | 1997-04-15 | 2001-07-17 | Terumo Kabushiki Kaisha | Balloon for medical tube and medical tube equipped with the same |
DE59711669D1 (en) * | 1997-06-23 | 2004-07-01 | Schneider Europ Gmbh Buelach | A catheter assembly |
US5919163A (en) | 1997-07-14 | 1999-07-06 | Delcath Systems, Inc. | Catheter with slidable balloon |
US5908407A (en) * | 1997-07-25 | 1999-06-01 | Neuroperfusion, Inc. | Retroperfusion catheter apparatus and method |
US6012034A (en) * | 1997-08-18 | 2000-01-04 | Becton, Dickinson And Company | System and method for selecting an intravenous device |
DE69828963T2 (en) * | 1997-10-01 | 2006-01-26 | Medtronic AVE, Inc., Santa Rosa | Drug delivery and gene therapy delivery system |
DE69725324T2 (en) * | 1997-10-23 | 2004-08-05 | Schneider (Europe) Gmbh | Seal for a catheter device with dilatation and occlusion balloon |
US6338709B1 (en) | 1998-02-19 | 2002-01-15 | Medtronic Percusurge, Inc. | Intravascular radiation therapy device and method of use |
US7713297B2 (en) | 1998-04-11 | 2010-05-11 | Boston Scientific Scimed, Inc. | Drug-releasing stent with ceramic-containing layer |
US6206283B1 (en) | 1998-12-23 | 2001-03-27 | At&T Corp. | Method and apparatus for transferring money via a telephone call |
US6280411B1 (en) | 1998-05-18 | 2001-08-28 | Scimed Life Systems, Inc. | Localized delivery of drug agents |
US8177743B2 (en) | 1998-05-18 | 2012-05-15 | Boston Scientific Scimed, Inc. | Localized delivery of drug agents |
US6527979B2 (en) | 1999-08-27 | 2003-03-04 | Corazon Technologies, Inc. | Catheter systems and methods for their use in the treatment of calcified vascular occlusions |
US7329236B2 (en) * | 1999-01-11 | 2008-02-12 | Flowmedica, Inc. | Intra-aortic renal drug delivery catheter |
US7122019B1 (en) | 2000-11-28 | 2006-10-17 | Flowmedica Inc. | Intra-aortic renal drug delivery catheter |
US7481803B2 (en) * | 2000-11-28 | 2009-01-27 | Flowmedica, Inc. | Intra-aortic renal drug delivery catheter |
US6749598B1 (en) * | 1999-01-11 | 2004-06-15 | Flowmedica, Inc. | Apparatus and methods for treating congestive heart disease |
US7780628B1 (en) | 1999-01-11 | 2010-08-24 | Angiodynamics, Inc. | Apparatus and methods for treating congestive heart disease |
US7637886B2 (en) * | 1999-01-25 | 2009-12-29 | Atrium Medical Corporation | Expandable fluoropolymer device and method of making |
US6955661B1 (en) * | 1999-01-25 | 2005-10-18 | Atrium Medical Corporation | Expandable fluoropolymer device for delivery of therapeutic agents and method of making |
US6231551B1 (en) | 1999-03-01 | 2001-05-15 | Coaxia, Inc. | Partial aortic occlusion devices and methods for cerebral perfusion augmentation |
US6743196B2 (en) | 1999-03-01 | 2004-06-01 | Coaxia, Inc. | Partial aortic occlusion devices and methods for cerebral perfusion augmentation |
US6786889B1 (en) | 1999-03-31 | 2004-09-07 | Scimed Life Systems, Inc | Textured and/or marked balloon for stent delivery |
US6533767B2 (en) * | 2000-03-20 | 2003-03-18 | Corazon Technologies, Inc. | Methods for enhancing fluid flow through an obstructed vascular site, and systems and kits for use in practicing the same |
GB9930654D0 (en) * | 1999-12-23 | 2000-02-16 | Halpin Richard M B | Device for controlling extra-vascular haemorrhage |
US8172783B1 (en) | 1999-12-30 | 2012-05-08 | Advanced Cardiovascular Systems, Inc | Conduit system for isolation of fluids in biological tissues |
US20060025749A1 (en) * | 2000-02-23 | 2006-02-02 | Moenning Stephen P | Trocar-cannula complex, cannula and method for delivering fluids during minimally invasive surgery |
US6302873B1 (en) | 2000-02-23 | 2001-10-16 | Stephen P. Moenning | Minimally invasive medical apparatus for dispensing a biologically active compound and an associated medical procedure for dispensing a biologically active compound |
US20050119613A1 (en) * | 2000-02-23 | 2005-06-02 | Moenning Stephen P. | Fluid delivery trocar-cannula complex, fluid delivery accessory, and method for delivering fluids during minimally invasive surgery |
AU2001245468A1 (en) * | 2000-03-20 | 2001-10-03 | Corazon Technologies, Inc. | Methods and systems for enhancing fluid flow through an obstructed vascular site |
US6485500B1 (en) * | 2000-03-21 | 2002-11-26 | Advanced Cardiovascular Systems, Inc. | Emboli protection system |
ATE318559T1 (en) | 2000-04-05 | 2006-03-15 | Kyphon Inc | DEVICES FOR TREATING BROKEN AND/OR DISEASE BONES |
US6544224B1 (en) | 2000-05-05 | 2003-04-08 | Advanced Cardiovascular Systems, Inc. | Lobed balloon catheter and method of use |
US6685672B1 (en) * | 2000-07-13 | 2004-02-03 | Edwards Lifesciences Corporation | Multi-balloon drug delivery catheter for angiogenesis |
US20030120256A1 (en) * | 2001-07-03 | 2003-06-26 | Syntheon, Llc | Methods and apparatus for sclerosing the wall of a varicose vein |
SE0003420L (en) * | 2000-09-25 | 2002-04-16 | Bjoern Flodin | Device for fixing a pipe means |
US6875197B1 (en) | 2000-11-14 | 2005-04-05 | Advanced Cardiovascular Systems, Inc. | Dimensionally stable and growth controlled inflatable member for a catheter |
CA2432033A1 (en) * | 2000-12-15 | 2002-06-20 | Donald R. Ricci | Endovascular prosthesis delivery system |
US6692458B2 (en) | 2000-12-19 | 2004-02-17 | Edwards Lifesciences Corporation | Intra-pericardial drug delivery device with multiple balloons and method for angiogenesis |
US7481790B2 (en) * | 2000-12-27 | 2009-01-27 | Advanced Cardiovascular Systems, Inc. | Vessel enlargement by arteriogenic factor delivery |
ES2328796T3 (en) | 2001-03-14 | 2009-11-18 | Myriad Genetics, Inc. | TSG101-GAG INTERACTION AND USE OF THE SAME. |
DE10115740A1 (en) | 2001-03-26 | 2002-10-02 | Ulrich Speck | Preparation for restenosis prophylaxis |
US6783513B2 (en) | 2001-05-17 | 2004-08-31 | Stephen P. Moenning | Body cavity access assembly and an associated medical procedure for dispensing a liquid |
US7727221B2 (en) | 2001-06-27 | 2010-06-01 | Cardiac Pacemakers Inc. | Method and device for electrochemical formation of therapeutic species in vivo |
EP1429832A4 (en) * | 2001-09-28 | 2010-06-09 | Rxtrocar Ltd | Trocar-cannula complex, cannula and method for delivering fluids during minimally invasive surgery |
AU2002367970A1 (en) | 2002-05-17 | 2003-12-02 | Bionethos Holding Gmbh | Medical device for the treatment of a body vessel or another tubular structure in the body |
US7131963B1 (en) * | 2002-06-27 | 2006-11-07 | Advanced Cardiovascular Systems, Inc. | Catheters and methods of using catheters |
EP1585572A4 (en) | 2002-09-20 | 2010-02-24 | Flowmedica Inc | Method and apparatus for intra aortic substance delivery to a branch vessel |
WO2004034767A2 (en) * | 2002-09-20 | 2004-04-29 | Flowmedica, Inc. | Catheter system for renal therapy |
US7063679B2 (en) | 2002-09-20 | 2006-06-20 | Flowmedica, Inc. | Intra-aortic renal delivery catheter |
US7993325B2 (en) | 2002-09-20 | 2011-08-09 | Angio Dynamics, Inc. | Renal infusion systems and methods |
DE10244847A1 (en) | 2002-09-20 | 2004-04-01 | Ulrich Prof. Dr. Speck | Medical device for drug delivery |
AU2003276903A1 (en) * | 2002-09-20 | 2004-05-04 | Flowmedica, Inc. | Method and apparatus for selective material delivery via an intra-renal catheter |
US7060051B2 (en) * | 2002-09-24 | 2006-06-13 | Scimed Life Systems, Inc. | Multi-balloon catheter with hydrogel coating |
US20040236279A1 (en) * | 2003-05-22 | 2004-11-25 | Atrium Medical Corp. | Gaseous therapeutic agent delivery |
US20040236410A1 (en) * | 2003-05-22 | 2004-11-25 | Atrium Medical Corp. | Polymeric body formation |
US20040236278A1 (en) * | 2003-05-22 | 2004-11-25 | Atrium Medical Corp. | Therapeutic agent delivery |
JP2006526464A (en) * | 2003-06-05 | 2006-11-24 | フローメディカ,インコーポレイテッド | System and method for performing bilateral intervention or diagnosis in a branched body lumen |
US7662143B2 (en) * | 2003-07-29 | 2010-02-16 | Boston Scientific Scimed, Inc. | Apparatus and method for treating intravascular disease |
EP1659970A4 (en) * | 2003-08-05 | 2008-05-21 | Flowmedica Inc | Sytem and method for prevention of radiocontrast induced nephropathy |
WO2005091910A2 (en) * | 2004-03-04 | 2005-10-06 | Flowmedica, Inc. | Sheath for use in peripheral interventions |
EP1727578A4 (en) * | 2004-03-10 | 2009-01-07 | Rxtrocar Ltd | Trocar-cannula complex, cannula and method for delivering biologically active agents during minimally invasive surgery |
EP1750506A4 (en) * | 2004-05-14 | 2010-03-17 | Flowmedica Inc | Bi-lateral local renal delivery for treating congestive heart failure and for bnp therapy |
US7537580B2 (en) * | 2004-06-23 | 2009-05-26 | Boston Scientific Scimed, Inc. | Intravascular dilatation infusion catheter |
US7758541B2 (en) * | 2004-08-17 | 2010-07-20 | Boston Scientific Scimed, Inc. | Targeted drug delivery device and method |
US7819841B2 (en) * | 2004-08-18 | 2010-10-26 | Medtronic Vascular, Inc. | Vessel isolation device |
AU2005277797A1 (en) * | 2004-08-19 | 2006-03-02 | Vein Rx, Inc. | An occludable intravascular catheter for drug delivery and method of using the same |
US20060069323A1 (en) * | 2004-09-24 | 2006-03-30 | Flowmedica, Inc. | Systems and methods for bi-lateral guidewire cannulation of branched body lumens |
KR20060072734A (en) * | 2004-12-23 | 2006-06-28 | 두산인프라코어 주식회사 | Appareatus for supplying compressed air of construction heavy equipments |
JP4728047B2 (en) * | 2005-06-02 | 2011-07-20 | オリンパスメディカルシステムズ株式会社 | Endoscope catheter with balloon |
US20070010845A1 (en) * | 2005-07-08 | 2007-01-11 | Gorman Gong | Directionally controlled expandable device and methods for use |
US20070065418A1 (en) * | 2005-09-20 | 2007-03-22 | Franco Vallana | Method and device for cellular therapy |
ITTO20050650A1 (en) | 2005-09-20 | 2007-03-21 | Sorin Biomedica Cardio Srl | DEVICE FOR CELL THERAPY |
US20070167913A1 (en) * | 2005-10-11 | 2007-07-19 | Flowmedica, Inc. | Vascular sheath with variable lumen construction |
US20070142819A1 (en) * | 2005-12-20 | 2007-06-21 | El-Nounou Fozan O | Bifurcated catheter for agent delivery and method of agent delivery |
US8172792B2 (en) | 2005-12-27 | 2012-05-08 | Tyco Healthcare Group Lp | Embolic protection systems for bifurcated conduits |
US8840660B2 (en) | 2006-01-05 | 2014-09-23 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US8089029B2 (en) | 2006-02-01 | 2012-01-03 | Boston Scientific Scimed, Inc. | Bioabsorbable metal medical device and method of manufacture |
US20070225750A1 (en) * | 2006-03-10 | 2007-09-27 | Brooke Ren | Embolic protection systems |
US20070224235A1 (en) | 2006-03-24 | 2007-09-27 | Barron Tenney | Medical devices having nanoporous coatings for controlled therapeutic agent delivery |
US8187620B2 (en) | 2006-03-27 | 2012-05-29 | Boston Scientific Scimed, Inc. | Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents |
US8048150B2 (en) | 2006-04-12 | 2011-11-01 | Boston Scientific Scimed, Inc. | Endoprosthesis having a fiber meshwork disposed thereon |
US7771401B2 (en) * | 2006-06-08 | 2010-08-10 | Angiodynamics, Inc. | Selective renal cannulation and infusion systems and methods |
US20100159450A1 (en) | 2006-06-23 | 2010-06-24 | Susanne Wagner | Dpyd gene variants and use thereof |
US8815275B2 (en) | 2006-06-28 | 2014-08-26 | Boston Scientific Scimed, Inc. | Coatings for medical devices comprising a therapeutic agent and a metallic material |
CA2655793A1 (en) | 2006-06-29 | 2008-01-03 | Boston Scientific Limited | Medical devices with selective coating |
JP2009545407A (en) | 2006-08-02 | 2009-12-24 | ボストン サイエンティフィック サイムド,インコーポレイテッド | End prosthesis with 3D decomposition control |
JP2010503469A (en) | 2006-09-14 | 2010-02-04 | ボストン サイエンティフィック リミテッド | Medical device having drug-eluting film |
WO2008034066A1 (en) * | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Bioerodible endoprostheses and methods of making the same |
DE602007011114D1 (en) | 2006-09-15 | 2011-01-20 | Boston Scient Scimed Inc | BIODEGRADABLE ENDOPROTHESIS WITH BIOSTABILES INORGANIC LAYERS |
WO2008034013A2 (en) | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Medical devices and methods of making the same |
JP2010503489A (en) | 2006-09-15 | 2010-02-04 | ボストン サイエンティフィック リミテッド | Biodegradable endoprosthesis and method for producing the same |
WO2008036548A2 (en) | 2006-09-18 | 2008-03-27 | Boston Scientific Limited | Endoprostheses |
US7981150B2 (en) | 2006-11-09 | 2011-07-19 | Boston Scientific Scimed, Inc. | Endoprosthesis with coatings |
ES2506144T3 (en) | 2006-12-28 | 2014-10-13 | Boston Scientific Limited | Bioerodible endoprosthesis and their manufacturing procedure |
US20080177186A1 (en) * | 2007-01-18 | 2008-07-24 | Slater Charles R | Methods and Apparatus for Determining a Treatment Volume of a Fluid Treatment Agent for Treating The Interior of a Blood Vessel |
US20080200873A1 (en) * | 2007-02-16 | 2008-08-21 | Alejandro Espinosa | Methods and Apparatus for Infusing the Interior of a Blood Vessel |
JP5330272B2 (en) * | 2007-02-22 | 2013-10-30 | コンバテック・テクノロジーズ・インコーポレイテッド | Seal for stoma orthosis |
US8070797B2 (en) | 2007-03-01 | 2011-12-06 | Boston Scientific Scimed, Inc. | Medical device with a porous surface for delivery of a therapeutic agent |
US8431149B2 (en) | 2007-03-01 | 2013-04-30 | Boston Scientific Scimed, Inc. | Coated medical devices for abluminal drug delivery |
US20080221551A1 (en) * | 2007-03-09 | 2008-09-11 | Flowmedica, Inc. | Acute kidney injury treatment systems and methods |
US8067054B2 (en) | 2007-04-05 | 2011-11-29 | Boston Scientific Scimed, Inc. | Stents with ceramic drug reservoir layer and methods of making and using the same |
US7976915B2 (en) | 2007-05-23 | 2011-07-12 | Boston Scientific Scimed, Inc. | Endoprosthesis with select ceramic morphology |
US8002823B2 (en) | 2007-07-11 | 2011-08-23 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US7942926B2 (en) | 2007-07-11 | 2011-05-17 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
WO2009012353A2 (en) | 2007-07-19 | 2009-01-22 | Boston Scientific Limited | Endoprosthesis having a non-fouling surface |
US8815273B2 (en) | 2007-07-27 | 2014-08-26 | Boston Scientific Scimed, Inc. | Drug eluting medical devices having porous layers |
US7931683B2 (en) | 2007-07-27 | 2011-04-26 | Boston Scientific Scimed, Inc. | Articles having ceramic coated surfaces |
WO2009018340A2 (en) | 2007-07-31 | 2009-02-05 | Boston Scientific Scimed, Inc. | Medical device coating by laser cladding |
JP2010535541A (en) | 2007-08-03 | 2010-11-25 | ボストン サイエンティフィック リミテッド | Coating for medical devices with large surface area |
US8052745B2 (en) | 2007-09-13 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis |
US20090105642A1 (en) * | 2007-10-22 | 2009-04-23 | Abbott Cardiovascular Systems Inc. | Low profile agent delivery perfusion catheter having reversibly expanding frames |
US20090105799A1 (en) * | 2007-10-23 | 2009-04-23 | Flowmedica, Inc. | Renal assessment systems and methods |
US20090118813A1 (en) * | 2007-11-02 | 2009-05-07 | Torsten Scheuermann | Nano-patterned implant surfaces |
US8029554B2 (en) | 2007-11-02 | 2011-10-04 | Boston Scientific Scimed, Inc. | Stent with embedded material |
US8216632B2 (en) | 2007-11-02 | 2012-07-10 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US7938855B2 (en) | 2007-11-02 | 2011-05-10 | Boston Scientific Scimed, Inc. | Deformable underlayer for stent |
US20090204099A1 (en) * | 2008-02-08 | 2009-08-13 | Michael Feloney | Cervical dilating and ripening catheter system and method |
US8157747B2 (en) * | 2008-02-15 | 2012-04-17 | Lary Research & Development, Llc | Single-use indicator for a surgical instrument and a surgical instrument incorporating same |
WO2009111716A1 (en) * | 2008-03-06 | 2009-09-11 | Boston Scientific Scimed, Inc. | Balloon catheter devices with sheath covering |
EP2271380B1 (en) | 2008-04-22 | 2013-03-20 | Boston Scientific Scimed, Inc. | Medical devices having a coating of inorganic material |
WO2009132176A2 (en) | 2008-04-24 | 2009-10-29 | Boston Scientific Scimed, Inc. | Medical devices having inorganic particle layers |
US7998192B2 (en) | 2008-05-09 | 2011-08-16 | Boston Scientific Scimed, Inc. | Endoprostheses |
US8236046B2 (en) | 2008-06-10 | 2012-08-07 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
EP2303350A2 (en) | 2008-06-18 | 2011-04-06 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US9067045B2 (en) * | 2008-07-25 | 2015-06-30 | Cook Medical Technologies Llc | Balloon catheter and method for making same |
US7985252B2 (en) | 2008-07-30 | 2011-07-26 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US8162879B2 (en) * | 2008-09-22 | 2012-04-24 | Tyco Healthcare Group Lp | Double balloon catheter and methods for homogeneous drug delivery using the same |
US8382824B2 (en) | 2008-10-03 | 2013-02-26 | Boston Scientific Scimed, Inc. | Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides |
US8226601B2 (en) | 2008-11-12 | 2012-07-24 | Sanovas, Inc. | Resector balloon system |
US8540667B2 (en) * | 2008-11-12 | 2013-09-24 | Sanovas, Inc. | Multi-balloon catheter for extravasated drug delivery |
US8231980B2 (en) | 2008-12-03 | 2012-07-31 | Boston Scientific Scimed, Inc. | Medical implants including iridium oxide |
EP2403546A2 (en) | 2009-03-02 | 2012-01-11 | Boston Scientific Scimed, Inc. | Self-buffering medical implants |
US8071156B2 (en) | 2009-03-04 | 2011-12-06 | Boston Scientific Scimed, Inc. | Endoprostheses |
US20100261662A1 (en) * | 2009-04-09 | 2010-10-14 | Endologix, Inc. | Utilization of mural thrombus for local drug delivery into vascular tissue |
US8287937B2 (en) | 2009-04-24 | 2012-10-16 | Boston Scientific Scimed, Inc. | Endoprosthese |
US20100292641A1 (en) * | 2009-05-15 | 2010-11-18 | Bandula Wijay | Targeted drug delivery device and method |
US8246576B2 (en) | 2009-05-18 | 2012-08-21 | Surmodics, Inc. | Method and apparatus for delivery of a therapeutic agent with an expandable medical device |
EP2451475A2 (en) | 2009-07-06 | 2012-05-16 | Novartis AG | Self replicating rna molecules and uses thereof |
SG178026A1 (en) | 2009-07-15 | 2012-03-29 | Novartis Ag | Rsv f protein compositions and methods for making same |
WO2011028419A1 (en) * | 2009-08-27 | 2011-03-10 | Boston Scientific Scimed, Inc. | Balloon catheter devices with drug-coated sheath |
US9457171B2 (en) | 2009-12-02 | 2016-10-04 | Renovorx, Inc. | Devices, methods and kits for delivery of therapeutic materials to a target artery |
EP2506913B8 (en) | 2009-12-02 | 2020-11-18 | RenovoRX, Inc. | Devices and kits for delivery of therapeutic materials to a pancreas |
US9539081B2 (en) | 2009-12-02 | 2017-01-10 | Surefire Medical, Inc. | Method of operating a microvalve protection device |
US10512761B2 (en) | 2009-12-02 | 2019-12-24 | Renovorx, Inc. | Methods for delivery of therapeutic materials to treat pancreatic cancer |
US8840637B2 (en) * | 2010-03-04 | 2014-09-23 | Grifols Therapeutics Inc. | Therapeutic delivery devices, systems, and methods |
US8668732B2 (en) | 2010-03-23 | 2014-03-11 | Boston Scientific Scimed, Inc. | Surface treated bioerodible metal endoprostheses |
WO2011159733A1 (en) | 2010-06-14 | 2011-12-22 | Maquet Cardiovascular Llc | Surgical instruments, systems and methods of use |
BR112013008700B8 (en) | 2010-10-11 | 2022-10-04 | Novartis Ag | SELF-REPLICATING RNA MOLECULE, ALPHAVIRUS REPLICON PARTICLE, COMPOSITION, RECOMBINANT DNA MOLECULE, USE OF SELF-REPLICATING RNA MOLECULE |
AU2012211278B2 (en) | 2011-01-26 | 2016-11-10 | Glaxosmithkline Biologicals Sa | RSV immunization regimen |
US20160074581A1 (en) | 2014-09-17 | 2016-03-17 | Lawrence J. Gerrans | Modulated Drug Delivery |
US8597239B2 (en) * | 2011-03-01 | 2013-12-03 | Sanovas, Inc. | Abrading balloon catheter for extravasated drug delivery |
US8348890B2 (en) | 2011-03-01 | 2013-01-08 | Sanovas, Inc. | Nested balloon catheter for localized drug delivery |
US10898693B2 (en) | 2011-03-01 | 2021-01-26 | Sanovas Intellectual Property, Llc | Nasal delivery of agents with nested balloon catheter |
US9180281B2 (en) | 2011-04-08 | 2015-11-10 | Sanovas, Inc. | Adjustable balloon catheter for extravasated drug delivery |
US20120259401A1 (en) | 2011-04-08 | 2012-10-11 | Gerrans Lawrence J | Balloon catheter for launching drug delivery device |
US20120259216A1 (en) | 2011-04-08 | 2012-10-11 | Gerrans Lawrence J | Balloon catheter with drug delivery probe |
LT2707385T (en) | 2011-05-13 | 2017-12-11 | Glaxosmithkline Biologicals Sa | Pre-fusion rsv f antigens |
US10213529B2 (en) | 2011-05-20 | 2019-02-26 | Surmodics, Inc. | Delivery of coated hydrophobic active agent particles |
US9861727B2 (en) | 2011-05-20 | 2018-01-09 | Surmodics, Inc. | Delivery of hydrophobic active agent particles |
EP3332802A1 (en) | 2011-07-06 | 2018-06-13 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
EP3508219A1 (en) | 2011-07-06 | 2019-07-10 | GlaxoSmithKline Biologicals S.A. | Self-replicating rna prime - protein boost vaccines |
CA2872033A1 (en) | 2011-10-11 | 2013-04-18 | Novartis Ag | Recombinant self-replicating polycistronic rna molecules |
US20140348863A1 (en) | 2011-10-12 | 2014-11-27 | Alessia Bianchi | Cmv antigens and uses thereof |
CN104853770A (en) | 2012-07-06 | 2015-08-19 | 诺华股份有限公司 | Immunogenic compositions and uses thereof |
US9332999B2 (en) | 2012-08-13 | 2016-05-10 | Covidien Lp | Apparatus and methods for clot disruption and evacuation |
US9332998B2 (en) | 2012-08-13 | 2016-05-10 | Covidien Lp | Apparatus and methods for clot disruption and evacuation |
US11246963B2 (en) | 2012-11-05 | 2022-02-15 | Surmodics, Inc. | Compositions and methods for delivery of hydrophobic active agents |
WO2014071387A1 (en) | 2012-11-05 | 2014-05-08 | Surmodics, Inc. | Composition and method for delivery of hydrophobic active agents |
WO2014197362A1 (en) | 2013-06-03 | 2014-12-11 | Ramtin Agah | Devices, methods and kits for delivery of therapeutic materials to a pancreas |
US9968740B2 (en) | 2014-03-25 | 2018-05-15 | Surefire Medical, Inc. | Closed tip dynamic microvalve protection device |
US9480825B2 (en) * | 2014-05-12 | 2016-11-01 | The Guy P. Curtis And Frances L. Curtis Trust | Catheter system for venous infusions |
US20150351775A1 (en) | 2014-06-04 | 2015-12-10 | Nfinium Vascular Technologies, Llc | Low radial force vascular device and method of occlusion |
MA40871A (en) | 2014-10-29 | 2017-09-05 | Novartis Ag | DIRECT EXPRESSION OF ANTIBODIES |
US20160287839A1 (en) | 2015-03-31 | 2016-10-06 | Surefire Medical, Inc. | Apparatus and Method for Infusing an Immunotherapy Agent to a Solid Tumor for Treatment |
EP3103500A1 (en) * | 2015-06-11 | 2016-12-14 | Lohmann & Rauscher GmbH | Balloon catheter with open pores |
WO2017161204A1 (en) * | 2016-03-16 | 2017-09-21 | Calture Vascular, Inc. | Device and method of thrombus retrieval |
US11400263B1 (en) | 2016-09-19 | 2022-08-02 | Trisalus Life Sciences, Inc. | System and method for selective pressure-controlled therapeutic delivery |
US10780250B1 (en) | 2016-09-19 | 2020-09-22 | Surefire Medical, Inc. | System and method for selective pressure-controlled therapeutic delivery |
JP6868694B2 (en) * | 2016-12-09 | 2021-05-12 | セント・ジュード・メディカル,カーディオロジー・ディヴィジョン,インコーポレイテッド | Pulmonary vein isolation balloon catheter |
US10898446B2 (en) | 2016-12-20 | 2021-01-26 | Surmodics, Inc. | Delivery of hydrophobic active agents from hydrophilic polyether block amide copolymer surfaces |
US10588636B2 (en) | 2017-03-20 | 2020-03-17 | Surefire Medical, Inc. | Dynamic reconfigurable microvalve protection device |
US10695543B2 (en) | 2017-05-18 | 2020-06-30 | Renovorx, Inc. | Methods for treating cancerous tumors |
US11052224B2 (en) | 2017-05-18 | 2021-07-06 | Renovorx, Inc. | Methods for treating cancerous tumors |
US20190298983A1 (en) * | 2018-01-15 | 2019-10-03 | Surefire Medical, Inc. | Injection Port for Therapeutic Delivery |
US11850398B2 (en) | 2018-08-01 | 2023-12-26 | Trisalus Life Sciences, Inc. | Systems and methods for pressure-facilitated therapeutic agent delivery |
US11338117B2 (en) | 2018-10-08 | 2022-05-24 | Trisalus Life Sciences, Inc. | Implantable dual pathway therapeutic agent delivery port |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US550238A (en) * | 1895-11-26 | Horace russel allen | ||
US2175726A (en) * | 1938-11-26 | 1939-10-10 | American Anode Inc | Catheter for bronchospirometry |
US2642874A (en) * | 1951-06-04 | 1953-06-23 | Wilmer B Keeling | Instrument for treating prostate glands |
US3948254A (en) * | 1971-11-08 | 1976-04-06 | Alza Corporation | Novel drug delivery device |
US3977408A (en) * | 1974-11-01 | 1976-08-31 | Mackew Allan H | Prosthetic catheter |
US4299226A (en) * | 1979-08-08 | 1981-11-10 | Banka Vidya S | Coronary dilation method |
US4501580A (en) * | 1980-12-12 | 1985-02-26 | Glassman Jacob A | Indwelling catheters |
US4531936A (en) * | 1981-01-29 | 1985-07-30 | Gordon Robert T | Device and method for the selective delivery of drugs to the myocardium |
DE3235974A1 (en) * | 1981-11-24 | 1983-06-01 | Volkmar Dipl.-Ing. Merkel (FH), 8520 Erlangen | DEVICE FOR REMOVAL OR FOR THE EXPANSION OF CONSTRAINTS IN BODY LIQUID LEADING VESSELS |
US4423725A (en) * | 1982-03-31 | 1984-01-03 | Baran Ostap E | Multiple surgical cuff |
US4445892A (en) * | 1982-05-06 | 1984-05-01 | Laserscope, Inc. | Dual balloon catheter device |
US4496345A (en) * | 1982-08-30 | 1985-01-29 | Hasson Harrith M | Ballooned cannula |
US4693243A (en) * | 1983-01-14 | 1987-09-15 | Buras Sharon Y | Conduit system for directly administering topical anaesthesia to blocked laryngeal-tracheal areas |
US4581017B1 (en) * | 1983-03-07 | 1994-05-17 | Bard Inc C R | Catheter systems |
US4883459A (en) * | 1983-07-29 | 1989-11-28 | Reynaldo Calderon | Retrograde perfusion |
US4627837A (en) * | 1984-05-30 | 1986-12-09 | German Gonzalo | Catheter device |
US4824436A (en) * | 1985-04-09 | 1989-04-25 | Harvey Wolinsky | Method for the prevention of restenosis |
US4781677A (en) * | 1985-07-17 | 1988-11-01 | Wilcox Gilbert M | Method of treatment utilizing a double balloon nasobiliary occlusion catheter |
US4705502A (en) * | 1985-11-06 | 1987-11-10 | The Kendall Company | Suprapubic catheter with dual balloons |
US4655746A (en) * | 1985-12-02 | 1987-04-07 | Target Therapeutics | Catheter device |
JPS62236560A (en) * | 1986-04-09 | 1987-10-16 | テルモ株式会社 | Catheter for repairing blood vessel |
US4723556A (en) * | 1986-04-14 | 1988-02-09 | Cordis Corporation | Intracranial ventricular catheter assembly |
US4821714A (en) * | 1986-12-04 | 1989-04-18 | Smelser Danny N | Pharmaceutical endotracheal tube |
DE8904026U1 (en) * | 1988-04-20 | 1989-05-24 | Schneider (Europe) Ag, Zuerich, Ch | |
DE68922497T2 (en) * | 1988-08-24 | 1995-09-14 | Marvin J Slepian | ENDOLUMINAL SEAL WITH BISDEGRADABLE POLYMERS. |
CH676426A5 (en) * | 1988-09-27 | 1991-01-31 | Schneider Shiley Ag | |
US5032113A (en) * | 1989-04-13 | 1991-07-16 | Scimed Life Systems, Inc. | Innerless catheter |
US5087244A (en) * | 1989-01-31 | 1992-02-11 | C. R. Bard, Inc. | Catheter and method for locally applying medication to the wall of a blood vessel or other body lumen |
US4994033A (en) * | 1989-05-25 | 1991-02-19 | Schneider (Usa) Inc. | Intravascular drug delivery dilatation catheter |
HU212760B (en) * | 1989-06-20 | 1997-02-28 | Denes | Method and device for the apportion of chemical materials into the vein wall |
US4973305A (en) * | 1989-12-08 | 1990-11-27 | David Goltzer | Method and apparatus for inserting and retaining an epidural catheter |
US5049132A (en) * | 1990-01-08 | 1991-09-17 | Cordis Corporation | Balloon catheter for delivering therapeutic agents |
US5163905A (en) * | 1990-01-12 | 1992-11-17 | Don Michael T Anthony | Regional perfusion dissolution catheter |
US5176638A (en) * | 1990-01-12 | 1993-01-05 | Don Michael T Anthony | Regional perfusion catheter with improved drug delivery control |
US5090960A (en) * | 1990-01-12 | 1992-02-25 | Don Michael T Anthony | Regional perfusion dissolution catheter |
US5236413B1 (en) * | 1990-05-07 | 1996-06-18 | Andrew J Feiring | Method and apparatus for inducing the permeation of medication into internal tissue |
US5135484A (en) * | 1990-05-09 | 1992-08-04 | Pioneering Technologies, Inc. | Method of removing plaque from vessels |
US5199951A (en) * | 1990-05-17 | 1993-04-06 | Wayne State University | Method of drug application in a transporting medium to an arterial wall injured during angioplasty |
US5092841A (en) * | 1990-05-17 | 1992-03-03 | Wayne State University | Method for treating an arterial wall injured during angioplasty |
US4976692A (en) * | 1990-09-13 | 1990-12-11 | Travenol Laboratories (Israel) Ltd. | Catheter particularly useful for inducing labor and/or for the application of a pharmaceutical substance to the cervix of the uterus |
US5180366A (en) * | 1990-10-10 | 1993-01-19 | Woods W T | Apparatus and method for angioplasty and for preventing re-stenosis |
WO1992011895A1 (en) * | 1990-12-28 | 1992-07-23 | Boston Scientific Corporation | Balloon drug delivery system |
EP0565604B1 (en) * | 1990-12-28 | 1999-07-28 | Boston Scientific Corporation | Catheter for drug delivery system |
US5324261A (en) * | 1991-01-04 | 1994-06-28 | Medtronic, Inc. | Drug delivery balloon catheter with line of weakness |
US5102402A (en) * | 1991-01-04 | 1992-04-07 | Medtronic, Inc. | Releasable coatings on balloon catheters |
US5250070A (en) * | 1991-05-28 | 1993-10-05 | Parodi Juan C | Less traumatic angioplasty balloon for arterial dilatation |
US5213576A (en) * | 1991-06-11 | 1993-05-25 | Cordis Corporation | Therapeutic porous balloon catheter |
US5318531A (en) * | 1991-06-11 | 1994-06-07 | Cordis Corporation | Infusion balloon catheter |
WO1993008864A1 (en) * | 1991-11-05 | 1993-05-13 | Myers Gene E | Fluted catheter |
US5254089A (en) * | 1992-04-02 | 1993-10-19 | Boston Scientific Corp. | Medication dispensing balloon catheter |
US5236424A (en) * | 1992-06-05 | 1993-08-17 | Cardiac Pathways Corporation | Catheter with retractable cannula for delivering a plurality of chemicals |
-
1993
- 1993-12-07 US US08/163,852 patent/US5397307A/en not_active Expired - Lifetime
-
1994
- 1994-10-14 AU AU77914/94A patent/AU682896B2/en not_active Ceased
- 1994-10-14 WO PCT/IB1994/000316 patent/WO1995015782A1/en active IP Right Grant
- 1994-10-14 CA CA002176753A patent/CA2176753C/en not_active Expired - Fee Related
- 1994-10-14 JP JP7516066A patent/JP2874800B2/en not_active Expired - Fee Related
- 1994-10-14 EP EP94928502A patent/EP0732958B1/en not_active Expired - Lifetime
- 1994-10-14 AT AT94928502T patent/ATE176761T1/en not_active IP Right Cessation
- 1994-10-14 DE DE69416603T patent/DE69416603T2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU682896B2 (en) | 1997-10-23 |
DE69416603D1 (en) | 1999-03-25 |
JPH09500312A (en) | 1997-01-14 |
WO1995015782A1 (en) | 1995-06-15 |
US5397307A (en) | 1995-03-14 |
JP2874800B2 (en) | 1999-03-24 |
CA2176753A1 (en) | 1995-06-15 |
DE69416603T2 (en) | 1999-09-09 |
AU7791494A (en) | 1995-06-27 |
ATE176761T1 (en) | 1999-03-15 |
EP0732958A1 (en) | 1996-09-25 |
EP0732958B1 (en) | 1999-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2176753C (en) | Drug delivery ptca catheter and method | |
EP0399712B1 (en) | Intravascular drug delivery dilation catheter | |
EP1027094B1 (en) | Apparatus for isolated pelvic perfusion | |
EP1005382B1 (en) | Balloon catheter | |
US5833658A (en) | Catheters for the delivery of solutions and suspensions | |
US5919163A (en) | Catheter with slidable balloon | |
US5653689A (en) | Infusion catheter | |
US5810767A (en) | Method and apparatus for pressurized intraluminal drug delivery | |
US5049132A (en) | Balloon catheter for delivering therapeutic agents | |
US20010041862A1 (en) | Novel apparatus and method of treating a tumor in the extremity of a patient | |
US6113576A (en) | Thrombolysis catheter system with fixed length infusion zone | |
US5779673A (en) | Devices and methods for application of intraluminal photopolymerized gels | |
CZ11696A3 (en) | Catheter | |
JPH08502679A (en) | Intravascular catheter with infusion array | |
JPH0698938A (en) | Method and apparatus for delivering medicine into blood vessel | |
JPH04261668A (en) | Catheter tube | |
WO1997017099A1 (en) | Balloon catheter for drug application | |
WO1996040346A1 (en) | Infusion sleeve catheter having distal distribution manifold | |
AU2020319872A1 (en) | Apparatus and methods for restoring tissue | |
JPH10179755A (en) | Infusion catheter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |